Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: General Health Status
Interventions: Osteopathic Manipulative Treatment, Light Touch; Procedure
Lead sponsor: A.T. Still University of Health Sciences; Other
Eligibility: 65 Years to 100 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Kirksville, Missouri

Conditions: Neural Response in Caudate, Weight Loss Trial, Impulsivity
Interventions: PhosphoLean, Placebo; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases
Interventions: Placebo, PF-04856883; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Chula Vista, California • Miami, Florida • Miramar, Florida + 4 more

Conditions: Pharmacokinetics of Alefacept
Interventions: alefacept, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Glendale, California

Conditions: Knowledge, Attitudes, Practice
Interventions: Animated Video; Behavioral
Lead sponsor: Michigan Technological University; Other
Eligibility: 18 Years and older
Enrollment: 479 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houghton, Michigan

Conditions: Endometriosis, Post Operative Pain
Interventions: Ketamine, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: oleoyl-estrone (MP-101); Drug
Lead sponsor: Manhattan Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 3
States / cities: New York, New York • Dallas, Texas • Salt Lake City, Utah

Conditions: Traumatic Brain Injury
Interventions: Carbamazepine, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 16 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Ileus
Interventions: MOA-728, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 75
States / cities: Benton, Arkansas • Colton, California • Laguna Hills, California + 62 more

Conditions: Anxiety
Interventions: GABA Probiotic Dose 1, GABA Probiotic Dose 2, Placebo Group; Dietary Supplement
Lead sponsor: Verb Biotics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prosthetic Joint Infection of Knee
Interventions: Intervention 1: Alternating Magnetic Field Treatment, Intervention 2 - Sham Treatment, Debridement, Antibiotics, Implant Retention; Device · Procedure
Lead sponsor: Solenic Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New Albany, Ohio • Tulsa, Oklahoma

Conditions: Onychomycosis
Interventions: NAB001, Placebo control; Drug
Lead sponsor: Promius Pharma, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Tucson, Arizona • Phoenix, Arkansas • Rogers, Arkansas + 22 more

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 36
States / cities: Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more

Conditions: Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions: Sirolimus in combination with ranibizumab, Placebo in combination with ranibizumab; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Dyskinesias, Parkinson Disease
Interventions: Part 1, JM-010 component Group A, Part 1, JM-010 component Group B, Part 1, JM-010 component Group C, Part 1, Placebo Group, Part 2, JM-010 combination Group A, Part 2, JM-010 combination Group B, Part 2, JM-010 component Group C, Part 2, Placebo Group; Drug
Lead sponsor: Bukwang Pharmaceutical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Miami, Florida • Detroit, Michigan

Conditions: Blood Flow Restriction, Growth Hormone, Strength Outcomes, Arginine
Interventions: BFR, Arginine, Placebo Pill; Procedure · Dietary Supplement
Lead sponsor: University of Mary Hardin-Baylor; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Belton, Texas

Conditions: Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania, Manic State, Psychoses, Manic-Depressive
Interventions: Quetiapine fumarate (Seroquel) SR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 51
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 48 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo; Drug
Lead sponsor: Othera Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more

Conditions: Vitamin D Deficiency
Interventions: cholecalciferol (vitamin D3), cholecalciferol; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 501 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Dry Eye
Interventions: Sirolimus; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Losmapimod; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more

Conditions: Bronchiectasis
Interventions: BI 1291583, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Peoria, Arizona • Newport Beach, California • Sacramento, California + 12 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Bazedoxifene Acetate; Drug
Lead sponsor: Riley Bove, MD; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Autism
Interventions: Gluten and dry milk, Placebo; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 3 Years to 12 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Preventative Osteopathic Manipulative Treatment (OMT) and the Nursing Home Patient

The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers

Effect of Animated Video on Comprehension and Implementation Feasibility

The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study

Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults

Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Probiotics for Anxiety Study

Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection

Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone

Phase 3 /Seroquel SR Acute Mania Monotherapy - US

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

Evaluation of Vitamin D Requirements During Pregnancy

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

Pilot Study of Diet and Behavior in Children With Autism